SL-1703

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameSL-1703
Drug Alias NameUmbilical Cord Blood CD19-BCMA CART Cell Therapy (Beijing GoBroad Hospital)SL1703SL-1703
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsScleroderma, SystemicLupus NephritisMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing GoBroad Hospital
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus NephritisMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A